Exosomes Archives | Page 15 of 27

Exosome Industry Progress is Accelerated by Landmark Events (Timeline)

October 9, 2022 By Cade Hildreth, Founder & President 1 Comment

Exosomes are small vesicles that are found in nearly all eukaryotic fluids and facilitate a range of important cellular functions. It has been long known that stem cells have the potential to exert therapeutic effects, but it only now being recognized that exosomes play an important role how these effects occur.

Over the past few years, this recognition has fueled a market for products and technologies leveraging stem cell exosomes. Key events in the formation of this market are highlighted in the timeline below. [Read more…]

RoosterBio and AGC Biologics Announce Collaboration to Accelerate Manufacturing of Cell and Exosome Therapies

September 3, 2022 By Cade Hildreth, Founder & President Leave a Comment

New partnership delivers clinically proven products and manufacturing processes for advanced therapies

SEATTLE, Aug. 16, 2022 — AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced today a strategic partnership with RoosterBio Inc., a leading supplier of human mesenchymal stem/stromal cells (hMSCs), highly engineered media, and bioprocess development services.

[Read more…]

Organicell Regenerative Medicine: Advances of Exosome-Based Therapeutics in the Clinic

July 22, 2022 By Cade Hildreth, Founder & President Leave a Comment

Author: Greta Gohring (Research Assistant, Organicell Regenerative Medicine)

Regenerative Medicine is a rapidly expanding sector of biotechnology with numerous innovative therapeutics. Regenerative medicine encompasses a multitude of specialties such as orthopedics, immunology, and cardiology, while following common trends within the fields of tissue and cell engineering. In contrast to common symptom-targeting therapeutics, which temporarily relieve and subdue conditions, regenerative medicine is designed to reprogram damaged or diseased tissues back to a healthy state. Through reprogramming, regenerative medicine has the potential to provide long-term effects in chronic and reoccurring symptomatic diseases. [Read more…]

Kimera Society Announces its 1st American Exosomes and RNA Conference

June 20, 2022 By Cade Hildreth, Founder & President 1 Comment

MIRAMAR, Fla., June 20, 2022 — Kimera® Society, a biotechnology non-profit research organization, is pleased to announce its first inaugural American Exosomes and RNA scientific, research and medical conference. [Read more…]

ShiftBio Partners with RoosterBio to Accelerate Development of a Novel Genetically Engineered Exosome, SBI-102 for Rare Diseases and Cancer

April 26, 2022 By Cade Hildreth, Founder & President Leave a Comment

RoosterBio’s MSC-derived exosome bioprocess technology platform enables accelerated development of ShiftBio’s lead therapeutic candidate via a scalable cGMP manufacturing process in bioreactors, downstream purification, and analytical characterization.

Seoul, South Korea and Frederick, MD, April 26, 2022 – ShiftBio, a leader in the development of innovative exosome platform technologies, announced today a strategic partnership with RoosterBio Inc., a leading supplier of human mesenchymal stem/stromal cells (MSCs), highly engineered media, and bioprocess development services. This partnership will accelerate ShiftBio’s therapeutic candidates, starting with SBI-102 (Stem cell-derived exosomes expressing a therapeutic ligand), into the clinic. [Read more…]